Strategic Funding Agreement with Aquestive

Summary by AI BETAClose X

RTW Biotech Opportunities Ltd announced a $75 million strategic funding agreement by Aquestive Therapeutics, in which RTW Bio participated through its commitment to the RTW-managed 4010 Royalty Fund. This funding will support Aquestive in bringing Anaphylmâ„¢ (epinephrine) Sublingual Film to market, a novel orally delivered film for the emergency treatment of Type 1 allergic reactions, pending U.S. FDA approval.

Disclaimer*

UK 100

Latest directors dealings